S
udden death resulting from medications prescribed with good intentions is an everpresent threat first recognized nearly a century ago (1, 2) . As early as 1923, when quinidine was first used as antiarrhythmic therapy, a disturbing phenomenon was noted: some patients treated with quinidine suffered from sudden collapses, sometimes ending in unexpected deaths (2) . These events were first attributed to "embolism" (2) or "nervous-system depression" (1) . It was only in 1964, when Selzer and Wray (3) first documented polymorphic ventricular tachyarrhythmias (VTA) as the cause for quinidine syncope.
The phenomenon of "drug-induced arrhythmia" became even more puzzling when medications with no cardiac indications, understandably assumed to be free of cardiac effects, were also reported to provoke arrhythmia (4) knowing that our treatment carries a small risk of provoking VTA. Not knowing how small this "small risk" really is has probably made this dilemma easier to cope with. Not anymore..
HOW SMALL IS "SMALL"?
In this issue of the Journal, Cheng et al. (12) Viskin et al. 
FOR THE TIMES THEY ARE A-CHANGIN'
Patients' transtelephonic ECG monitoring from home for QT-monitoring, using small dedicated devices (26) or even mobile phones, is feasible and could be offered to high-risk patients. True, most physicians cannot recognize a long QT (27) , but that can be changed with proper training (28) . Alternatively, dedicated services of home-QT-monitoring could be offered. The technological obstacles, however, are only part of the problem. Although the risk for drug-induced VTA increases as the QT prolongs, there is no absolute cutoff value. For example, among 5,000 patients receiving azimilide, the risk for VTA rose as the QTc increased >500 ms and then increased rapidly with a QTc >520 ms (29); yet, 45% and 60% of patients with VTA had a QTc below these 2 cutoff values (29) . Finally, full disclosure of the available information could prove counterproductive by lessening therapeutic compliance (30) . In other words, the perception that "this drug could 
